Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus dostarlimab in PD-L1–positive NSCLC or malignant pleural mesothelioma with DNA repair gene mutations
2020-000109-10Phase 2Active
- Sponsor
- University of Turin, Department of Oncology
- Start
- Oct 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib and dostarlimab in non-small cell lung cancer (NSCLC) and pleural mesothelioma, sponsored by University of Turin, Department of Oncology. Primary endpoint: Progression-free survival. Started Oct 2020; status: active.
02
Drugs
niraparibdostarlimab
03
Conditions
non-small cell lung cancer (NSCLC)pleural mesothelioma
Beyond the preview
Go deeper on 2020-000109-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000109-10.